Compare SHOO & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHOO | VCRE |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 1996 | N/A |
| Metric | SHOO | VCRE |
|---|---|---|
| Price | $43.58 | $11.52 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $42.14 | N/A |
| AVG Volume (30 Days) | ★ 897.4K | 3.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $2,534,109,000.00 | N/A |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $42.75 | ★ N/A |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $22.26 | $11.00 |
| 52 Week High | $47.11 | $12.85 |
| Indicator | SHOO | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 22.97 |
| Support Level | $43.03 | $11.00 |
| Resistance Level | $44.62 | $12.85 |
| Average True Range (ATR) | 1.44 | 0.51 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 88.63 | 28.10 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.